# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ascendiant Capital analyst Edward Woo maintains Surgepays (NASDAQ:SURG) with a Buy and lowers the price target from $10 to $...
Surgepays (NASDAQ:SURG) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.20 by ...
Ascendiant Capital analyst Edward Woo maintains Surgepays (NASDAQ:SURG) with a Buy and lowers the price target from $11.5 to...
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported b...
Maxim Group analyst Michael Diana downgrades Surgepays (NASDAQ:SURG) from Buy to Hold.
U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 50 points on Wednesday. Following the market o...
Shares of SurgePays, Inc. (NASDAQ: SURG) fell sharply in today’s pre-market trading after the company reported worse-than-exp...